Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

CONTEXT Surgery is a cornerstone in the treatment of acromegaly, but its efficacy in large, invasive tumors is scant. OBJECTIVE The objective of this study was to investigate whether partial surgical removal of GH-secreting pituitary tumors enhances the response rate to somatostatin analogs (SSA; sc octreotide, slow-release octreotide, and lanreotide). DESIGN This was a multicenter, open, retrospective study. SETTING The study was performed at university hospitals. SUBJECTS AND METHODS Eighty-six patients (42 women and 44 men; age, 42 +/- 14 yr) with acromegaly were studied. INTERVENTIONS Patients underwent two courses of octreotide, lanreotide, or slow-release octreotide treatments before and after surgery of at least 6 months. MAIN OUTCOME MEASURE The main outcome measure was normal IGF-I levels for age. RESULTS Presurgical SSA treatment significantly decreased GH and IGF-I levels in all patients. GH levels were less than 2.5 microg/liter in 12 patients (14%); IGF-I levels normalized in nine (10%). After surgery, GH and IGF-I levels further decreased in all patients; tumor removal was greater than 75% in 50 (58%), 50.1-75% in 21 (24%), 25.1-50% in 10 (12%), and less than 25% in five patients (6%). Preoperatively, pituitary function was impaired in 12 patients (14%). Postsurgical SSA treatment lowered GH levels to less than 2.5 microg/liter in 49 (56%) and normalized IGF-I levels in 48 patients (55%). The success rate was significantly increased compared with that before surgery (P < 0.0001). GH (r = -0.48; P < 0.0001) and IGF-I levels (r = -0.38; P = 0.0003) after postsurgery SSA treatment correlated with the amount of tumor surgically removed. After surgery, pituitary function was impaired in 28 patients (32.6%) and was improved in 12 patients (13.9%). The cumulative prevalence of pituitary deficiency did not change during the study (normal function from 40 to 42%; deficiency from 60 to 58%). CONCLUSIONS Surgical tumor removal (>75%) enhances the response to SSAs without impairing pituitary function. Our data indicate that surgical debulking has a significant place in the treatment algorithm of acromegaly.

[1]  L. Niskanen,et al.  A nationwide survey of mortality in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[2]  P. Chanson,et al.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[3]  J. Bevan.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[4]  R. Fahlbusch,et al.  The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. , 2005, European journal of endocrinology.

[5]  S. Grottoli,et al.  Cost-of-illness study in acromegalic patients in Italy , 2004, Journal of endocrinological investigation.

[6]  R. Clayton,et al.  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[7]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[8]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[9]  S. Grottoli,et al.  Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. , 2003, The Journal of clinical endocrinology and metabolism.

[10]  G. Lasio,et al.  Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? , 2003, The Journal of clinical endocrinology and metabolism.

[11]  E. Motti,et al.  Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. , 2003, Journal of Clinical Endocrinology and Metabolism.

[12]  J. Neal,et al.  Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. , 2003, The Journal of clinical endocrinology and metabolism.

[13]  S. Melmed,et al.  Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  J. Hardy,et al.  Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly , 2003, Clinical endocrinology.

[15]  P. Chanson,et al.  Guidelines for acromegaly management. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  P. Freda.  Somatostatin analogs in acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  M. Vance,et al.  Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  P. Cappabianca,et al.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. , 2001, The Journal of clinical endocrinology and metabolism.

[19]  P. Chanson,et al.  Efficacy and Tolerability of the Long-Acting Somatostatin Analog Lanreotide in Acromegaly. A 12-Month Multicenter Study of 58 Acromegalic Patients , 2000, Pituitary.

[20]  F. Casanueva,et al.  Criteria for cure of acromegaly: a consensus statement. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  Stratton,et al.  Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience , 1999, Clinical endocrinology.

[22]  P. Stewart,et al.  Clinical and biochemical response following withdrawal of a long‐acting, depot injection form of octreotide (Sandostatin‐LAR®) , 1999, Clinical endocrinology.

[23]  Davis,et al.  The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma , 1998, Clinical endocrinology.

[24]  A. Colao,et al.  Growth-hormone and prolactin excess , 1998, The Lancet.

[25]  P. Black,et al.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  S. Wardlaw,et al.  Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. , 1998, Journal of neurosurgery.

[27]  S. Wardlaw,et al.  Primary medical therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  R. McNally,et al.  Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study , 1998 .

[29]  P. Cappabianca,et al.  Effect of octreotide pretreatment on surgical outcome in acromegaly. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  A. Grossman,et al.  Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure , 1996, Clinical endocrinology.

[31]  M. Salvatore,et al.  Prediction of efficacy of octreotide therapy in patients with acromegaly. , 1996, The Journal of clinical endocrinology and metabolism.

[32]  P. Chanson,et al.  Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. , 2005, European journal of endocrinology.

[33]  B. Biondi,et al.  Subclinical hyperthyroidism: clinical features and treatment options. , 2005, European journal of endocrinology.

[34]  P. Chanson,et al.  Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. , 2000, Pituitary.

[35]  H. R. Donald.  Pituitary insufficiency. , 1955, The New Zealand medical journal.

[36]  D. Torigian,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Octreotide as Primary Therapy for Acromegaly* , 2022 .